SYNTHESIS OF WATER-SOLUBLE (AMINOALKYL)CAMPTOTHECIN ANALOGS - INHIBITION OF TOPOISOMERASE-I AND ANTITUMOR-ACTIVITY

被引:513
作者
KINGSBURY, WD [1 ]
BOEHM, JC [1 ]
JAKAS, DR [1 ]
HOLDEN, KG [1 ]
HECHT, SM [1 ]
GALLAGHER, G [1 ]
CARANFA, MJ [1 ]
MCCABE, FL [1 ]
FAUCETTE, LF [1 ]
JOHNSON, RK [1 ]
HERTZBERG, RP [1 ]
机构
[1] SMITHKLINE BEECHAM PHARMACEUT,DEPT BIOMOLEC DISCOVERY,KING OF PRUSSIA,PA 19406
关键词
D O I
10.1021/jm00105a017
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Water-soluble analogues of the antitumor alkaloid camptothecin (1) were prepared in which aminoalkyl groups were introduced into ring A or B. Most of the analogues were prepared by oxidation of camptothecin to 10-hydroxy-camptothecin (2) followed by a Mannich reaction to give N-substituted 9-(aminomethyl)-10-hydroxycamptothecins (4-12) or by subsequent modification of Mannich product 4 (13, 15, 17, 19, 21). Others were obtained by modification of the hydroxyl group of 2 (25, 26) or by total synthesis (35, 42, 43). These analogues, as well as some of their synthetic precursors, were evaluated for inhibition of topoisomerase I, cytotoxicity, and antitumor activity. Although there was not a quantitative correlation between these assays, compounds that inhibited topoisomerase I were also cytotoxic and demonstrated antitumor activity in vivo. Further evaluation of the most active water-soluble analogue led to the selection of 9-[(dimethylamino)methyl]-10-hydroxycamptothecin (4, SK&F 104864) for development as an antitumor agent. In addition to its water solubility, ease of synthesis from natural camptothecin, and high potency, 4 demonstrated broad-spectrum activity in preclinical tumor models and is currently undergoing Phase I clinical trials in cancer patients.
引用
收藏
页码:98 / 107
页数:10
相关论文
共 40 条
  • [1] CHARACTERIZATION OF A MAMMALIAN MUTANT WITH A CAMPTOTHECIN-RESISTANT DNA TOPOISOMERASE-I
    ANDOH, T
    ISHII, K
    SUZUKI, Y
    IKEGAMI, Y
    KUSUNOKI, Y
    TAKEMOTO, Y
    OKADA, K
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) : 5565 - 5569
  • [2] BROWN J, 1990, P AM SOC CLIN ONCOL, V9, P336
  • [3] PALLADIUM-CATALYZED TRIETHYLAMMONIUM FORMATE REDUCTION OF ARYL TRIFLATES - A SELECTIVE METHOD FOR THE DEOXYGENATION OF PHENOLS
    CACCHI, S
    CIATTINI, PG
    MORERA, E
    ORTAR, G
    [J]. TETRAHEDRON LETTERS, 1986, 27 (45) : 5541 - 5544
  • [4] Cai J-C., 1983, ALKALOIDS CHEM PHARM, VVol. 21, P101
  • [5] CAI JC, 1983, CHEM HETEROCYCL COMP, V25, P753
  • [6] CHAMPOUX JJ, 1989, J BIOL CHEM, V264, P1010
  • [7] ENG WK, 1988, MOL PHARMACOL, V34, P755
  • [8] GERAN RI, 1972, CANC CHEMOTHER REP, V3, P1
  • [9] DNA TOPOISOMERASE-I TARGETED CHEMOTHERAPY OF HUMAN-COLON CANCER IN XENOGRAFTS
    GIOVANELLA, BC
    STEHLIN, JS
    WALL, ME
    WANI, MC
    NICHOLAS, AW
    LIU, LF
    SILBER, R
    POTMESIL, M
    [J]. SCIENCE, 1989, 246 (4933) : 1046 - 1048
  • [10] GOTTLIEB JA, 1972, CANCER CHEMOTH REP 1, V56, P103